Daiichi Sankyo Co.

This MedLibrary.org supplementary page on Daiichi Sankyo Co. is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:

Daiichi Sankyo Company Limited (第一三共株式会社 Daiichi Sankyō Kabushiki-gaisha?) (TYO: 4568) is a joint holding company established in 2005 by Sankyo Co., Ltd. (三共株式会社 Sankyō Kabushiki-gaisha?) and Daiichi Pharmaceutical Co., Ltd. (第一製薬株式会社 Daiichi Seiyaku Kabushiki-gaisha?), which are pharmaceutical companies based in Japan. Its main offices are located in Chūō, Tokyo.

Contents

Acquisitions

On June 10, 2008, Daiichi Sankyo Co., agreed to take a majority (35%) stake in Indian generic drug maker Ranbaxy, with a deal valued at about $4.6 billion. Ranbaxy's Malvinder Singh will remain CEO after the transaction.[1][2] Also in June 2008, the company expressed intent to acquire U3 Pharma, which would contribute a therapeutic anti-HER3 antibody to the company's anticancer portfolio.[3]

Major products of Daiichi Sankyo Group

Sankyo

Daiichi Pharmaceutical

Notes

External links


Wikipedia content modification information:

  • This page was last modified on 11 October 2008, at 15:37.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Daiichi Sankyo Co.".

The URL for this specific entry is:

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.